Crossmark

Correction to: The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan

Crossref DOI link: https://doi.org/10.1007/s13300-025-01697-9

Published Online: 2025-02-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aranishi, Toshihiko https://orcid.org/0000-0001-8862-9468
Igarashi, Ataru https://orcid.org/0000-0001-6307-6916
Hara, Kazuo

Osumili, Beatrice https://orcid.org/0000-0002-5862-9325
Cai, Zhihong https://orcid.org/0000-0002-3431-197X
Mizogaki, Aska

Sato, Manaka https://orcid.org/0000-0001-7000-4769
Takeuchi, Masakazu https://orcid.org/0000-0003-3176-3118
Minghetti, Alice https://orcid.org/0000-0001-7913-5861
Hunt, Barnaby https://orcid.org/0000-0001-5420-279X
Kadowaki, Takashi
License Information

Text and Data Mining valid from 2025-02-07

Version of Record valid from 2025-02-07
More Information

Article History

First Online: 7 February 2025